

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/667,966 Confirmation No.: 7892
Applicant : Dong XIE et al.
Filed : September 23, 2003
Title : PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV
INFECTION
TC/Art Unit : 1645
Examiner: : To Be Assigned
Docket No. : 63024.000002
Customer No. : 21967

REQUEST FOR CORRECTED FILING RECEIPT

ATTN: Office of Initial Patent Examination's Filing Receipt Corrections

Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Upon review of the Official Filing Receipt dated January 18, 2005, for the above-referenced patent application, an error was discovered with respect to the Power of Attorney. Please change the Power of Attorney to --The patent practitioners associated with Customer No. 21967--. A marked-up copy of the Official Filing Receipt is included.


It is respectfully requested that a Corrected Official Filing Receipt be issued and forwarded to the undersigned. Since the foregoing is an error of the U.S. Patent and Trademark Office, it is further respectfully requested that no fees are required for the entry of this Request.

However, if it is determined otherwise, the Commissioner is hereby authorized to charge such fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: 4/17/06

By: 
Robert C. Lampe, III
Registration No. 51,914

Christopher J. Nichols, Ph.D.
Registration No. 55,984

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Telephone (202) 955-1500
Fax (202) 778-2201

RCL/CJN:cdh




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/667,966	09/23/2003	1645	1055	63024.000002	1	36	7

21967
HUNTON & WILLIAMS LLP
INTELLECTUAL PROPERTY DEPARTMENT
1900 K STREET, N.W.
SUITE 1200
WASHINGTON, DC 20006-1109



CONFIRMATION NO. 7892



0000000014977931*

DOCKETED

Date Mailed: 01/18/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Dong Xie, Germantown, MD;
He Jiang, Rockville, MD;

Assignment For Published Patent Application

Frontier Biotechnologies Co., Ltd., Chongqing, CHINA

Power of Attorney:

~~Rodger Tate-27399~~
~~Thomas Scott-27636~~
~~Stanislaus Aksman-28502~~
~~John Pinkerton-28746~~
~~Robert Schulman-31196~~

~~Jennifer Albert-32042~~
~~Kevin Dunleavy-32024~~
~~James Gatto-32094~~
~~Thomas Blasey-33475~~
~~Laurence Posorske-34090~~

The patent practitioners
associated with customer
NO. 21967.

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/412,797 09/24/2002

Foreign Applications

If Required, Foreign Filing License Granted: 04/26/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/667,966

Projected Publication Date: 04/28/2005

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Peptide derivative fusion inhibitors of HIV infection

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).